GOSSAMER BIO, INC. Operating Lease, Expense
GOSSAMER BIO, INC. (GOSS) reported Operating Lease, Expense of $1.10 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-11-07
- GOSSAMER BIO, INC. operating lease, expense for the quarter ending 2024-09-30 was $1.10M, a 22.22% increase year-over-year.
- GOSSAMER BIO, INC. operating lease, expense for the quarter ending 2024-06-30 was $900.00K, a 0.00% change year-over-year.
- GOSSAMER BIO, INC. operating lease, expense for the quarter ending 2024-03-31 was $900.00K, a 0.00% change year-over-year.
- GOSSAMER BIO, INC. operating lease, expense for the quarter ending 2023-12-31 was $800.00K, a 0.00% change year-over-year.
- GOSSAMER BIO, INC. operating lease, expense for fiscal 2023 was $3.40M, a 3.03% increase from fiscal 2022.
- GOSSAMER BIO, INC. operating lease, expense for fiscal 2022 was $3.30M, a 23.26% decline from fiscal 2021.
- GOSSAMER BIO, INC. operating lease, expense for fiscal 2021 was $4.30M, a 7.50% increase from fiscal 2020.
- GOSSAMER BIO, INC. operating lease, expense for fiscal 2020 was $4.00M, a 29.03% increase from fiscal 2019.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $1.10M 10-Q · filed 2024-11-07 | $2.00M derived: sum of 2 quarters · filed 2024-11-07 | $2.80M 10-Q · filed 2024-11-07 | $3.70M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | $900.00K 10-Q · filed 2024-08-12 | $1.70M 10-Q · filed 2024-08-12 | $2.60M derived: sum of 3 quarters · filed 2024-08-12 | $3.50M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-03-31 | $900.00K 10-Q · filed 2024-05-07 | $1.70M derived: sum of 2 quarters · filed 2024-05-07 | $2.60M derived: sum of 3 quarters · filed 2024-11-07 | $3.50M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.70M derived: sum of 2 quarters · filed 2024-11-07 | $2.60M derived: sum of 3 quarters · filed 2024-11-07 | $3.40M 10-K · filed 2024-03-05 | |
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-07 | $1.80M derived: sum of 2 quarters · filed 2024-11-07 | $2.60M 10-Q · filed 2024-11-07 | $3.50M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-12 | $1.70M 10-Q · filed 2024-08-12 | $2.60M derived: sum of 3 quarters · filed 2024-08-12 | $3.40M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-07 | $1.70M derived: sum of 2 quarters · filed 2024-05-07 | $2.50M derived: sum of 3 quarters · filed 2024-05-07 | $3.30M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.60M derived: sum of 2 quarters · filed 2024-03-05 | $2.40M derived: sum of 3 quarters · filed 2024-03-05 | $3.30M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $800.00K 10-Q · filed 2023-11-09 | $1.60M derived: sum of 2 quarters · filed 2023-11-09 | $2.50M 10-Q · filed 2023-11-09 | $3.50M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | $800.00K 10-Q · filed 2023-08-08 | $1.70M 10-Q · filed 2023-08-08 | $2.70M derived: sum of 3 quarters · filed 2024-03-05 | $3.80M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | $900.00K 10-Q · filed 2023-05-09 | $1.90M derived: sum of 2 quarters · filed 2024-03-05 | $3.00M derived: sum of 3 quarters · filed 2024-03-05 | $4.10M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.10M derived: sum of 2 quarters · filed 2024-03-05 | $3.20M derived: sum of 3 quarters · filed 2024-03-05 | $4.30M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-03 | $2.20M derived: sum of 2 quarters · filed 2022-11-03 | $3.30M 10-Q · filed 2022-11-03 | $5.30M derived: sum of 4 quarters · filed 2023-03-17 | |
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-09 | $2.20M 10-Q · filed 2022-08-09 | $4.20M derived: sum of 3 quarters · filed 2023-03-17 | $5.20M derived: sum of 4 quarters · filed 2023-03-17 | |
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-10 | $3.10M derived: sum of 2 quarters · filed 2023-03-17 | $4.10M derived: sum of 3 quarters · filed 2023-03-17 | $4.90M derived: sum of 4 quarters · filed 2023-03-17 | |
| 2020-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $3.10M derived: sum of 2 quarters · filed 2023-03-17 | $3.90M derived: sum of 3 quarters · filed 2023-03-17 | $4.00M 10-K · filed 2023-03-17 | |
| 2020-09-30 | $1.00M 10-Q · filed 2021-11-08 | $1.80M derived: sum of 2 quarters · filed 2021-11-08 | $1.90M 10-Q · filed 2021-11-08 | $2.90M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $800.00K 10-Q · filed 2021-08-09 | $1.80M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $800.00K 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $3.10M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |